medwireNews: The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes (PROs) than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer (SCLC).
These results – presented at the ESMO Congress 2019 in Barcelona, Spain – are consistent with the improved survival and efficacy outcomes already observed with the combination, said study author Marina Garassino, from Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.
She reported that patients who were randomly assigned to receive up to four cycles of durvalumab 1500 mg alongside etoposide plus cisplatin or carboplatin every 3 weeks had a longer time to deterioration for the global score and all subscales of the EORTC QLQ-C30 questionnaire than their counterparts given chemotherapy alone, with the differences reaching statistical significance for all the subscales.
Similarly, time to deterioration of symptoms – as assessed by the EORTC QLQ-C30 and QLQ-LC13 scales – also favored the combination therapy, with statistical significance achieved for some symptoms, such as appetite loss, constipation, diarrhea, hemoptysis, and chest pain.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group